胸外浆细胞瘤(EMP)是一种浆细胞瘤，并且其发病机制还没有完全阐明。根据它是否独立于骨髓瘤病，可分为原发性和继发性EMP，具有不同的生物学和临床特征。原发性EMP侵袭性低，细胞遗传学和分子遗传学异常较少，预后良好，手术和/或放疗是主要治疗方法。继发性EMP即多发性骨髓瘤(MM)的胸外浸润进展，常伴有高危细胞和分子遗传学异常以及预后不良，化疗、免疫治疗和造血干细胞移植是主要治疗方法。本文综述了EMP在发病机制、细胞遗传学分子遗传学和治疗方面的最新研究进展，为临床工作提供参考。

Extramedullary plasma cell tumor (EMP) is a kind of plasma cell tumor, and its pathogenesis is not completely clear. According to whether it is independent of myeloma disease, it can be divided into primary and secondary EMP, which have different biological and clinical characteristics. Primary EMP has low invasion, fewer cytogenetic and molecular genetic abnormalities and good prognosis, and surgery and / or radiotherapy are the mainly treatments. Secondary EMP, as the extramedullary invasive progression of multiple myeloma (MM), is often accompanied by high-risk cellular and molecular genetic abnormalities and poor prognosis, chemotherapy, immunotherapy and hematopoietic stem cell transplantation are the mainly treatment. This paper reviews the latest research progress of EMP in the pathogenesis, cytogenetics molecular genetics and treatment, so as to provide reference for clinical work.